Posts

PureTech Spins Off Celea with $180M Funding to Advance IPF Drug Deupirfenidone into Phase 3

on

Bayer Returns to Pharma M&A with Up to $2.45B Acquisition of Perfuse Therapeutics

on

Bayer and Vanderbilt University Medical Center Announce Five-Year Collaboration to Advance Cardiovascular and Kidney Disease Treatments

on

Bayer Receives Breakthrough Therapy Designation in US and China for Sevabertinib in First-Line HER2-Mutant NSCLC

on

Bayer Receives Breakthrough Therapy Designation in US and China for Sevabertinib in First-Line HER2-Mutant NSCLC

on

Bayer's Finerenone Approved in Japan for Chronic Heart Failure Treatment

on

Bayer Stock Rallies as Next-Gen Blood Thinner Achieves Phase 3 Success

on

Bayer's Pharma Division Grows as Restructuring Drives Major Changes

on

Bayer Receives FDA Approval for Lynkuet, a Novel Non-Hormonal Drug for Menopausal Hot Flashes

on

FDA Approves Bayer's Lynkuet for Menopausal Hot Flashes

on

FDA Approves Bayer's Lynkuet for Menopausal Hot Flashes

on

Bayer Expands Oncology Pipeline with $1.3B Kumquat Deal

on

Bayer-allied NextRNA Therapeutics winds down operations after missing a milestone in their collaboration

on

Bayer Layoffs Top 12,000 with More Cuts Expected Amid Ongoing Restructuring

on

Bayer Extends CEO Bill Anderson's Contract; Sarepta C-Suite Turmoil

on

Bayer's Lynkuet (elinzanetant) Wins First-in-World Approval in UK, Challenging Astellas' Hot Flash Drug

on

Bayer's BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move

on

Forging the Future of Cell Therapy: Bayer and BlueRock's Unique Journey

on

Forging the Future of Cell Therapy: Bayer and BlueRock's Unique Journey

on

Bayer Restructuring Cuts 2,000 Jobs, Thins Management Layers in 2025

on